- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00638157
Phase 4 Efficacy and Safety Study of Cubicin® With and Without Combination Therapy in S. Aureus Infective Endocarditis (SAIE)
A Phase 4 Multicenter, Randomized, Double Blind Study to Describe the Efficacy and Safety of Cubicin® (Daptomycin for Injection) With and Without Initial Gentamicin Combination Therapy in the Treatment of S. Aureus Infective Endocarditis
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Patients will be randomized to either of the following two treatment arms:
- Arm 1: daptomycin
- Arm 2: daptomycin with initial i.v. gentamicin
Patients who meet all the inclusion criteria and exhibit none of the exclusion criteria may be enrolled. Intravenous drug user (IVDU) patients may be randomized and study drug begun on the basis of two separate peripheral blood cultures positive for S. aureus obtained within 96 hours prior to the first dose of study drug.
The recommended minimum duration of treatment for daptomycin will be 28 days. The duration of treatment for gentamicin will be 3 days.
During study treatment, regular assessments (including weekly safety laboratory testing including CPK) will be performed. An End-of-Therapy (EOT) evaluation will be performed on the day of or 1-2 days after completion of daptomycin study drug or upon early termination (ET). All patients will have a post-therapy visit for Test of Cure (TOC)/Safety performed 21-28 days following the last dose of daptomycin study drug.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Colorado
-
Denver, Colorado, United States, 80204
- Denver Health Medical Center
-
-
Michigan
-
Detroit, Michigan, United States, 48202
- Henry Ford Health System
-
Detroit, Michigan, United States, 48201
- Wayne State University
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19140
- Temple University School of Medicine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Written informed consent has been obtained;
- Male or female ≥18 years of age;
- IVDU (as confirmed by history of drug abuse within the past 3 months or recent needle track marks);
- Definite or possible IE according to the modified Duke Criteria (see Appendix A); [17 ];
- Two blood cultures positive for S. aureus obtained within 96 hours prior to first dose of study medication acquired by fresh venipuncture using aseptic technique and analyzed at the local laboratory (see Appendix B).
Exclusion Criteria:
- Intravascular foreign material in place at the time that the positive blood culture was drawn (e.g., intracardiac pacemaker wires, percutaneous or implanted venous catheters, vascular grafts), (exception: vascular stents that have been in place for >6 months or permanent pacemaker wires attached via epicardial leads are allowed);
High likelihood of LIE as indicated by:
- Prior diagnosis of predisposing left-sided valvular pathology (e.g., rheumatic heart disease, bicuspid aortic valve); or
- Findings on screening examination of left-sided valvular pathology (e.g., diastolic murmur of aortic insufficiency); or
- Findings on screening examination of major systemic emboli to visceral organs (e.g. cerebral or splenic infarct). Patients may be included if their only findings are consistent with microvascular phenomena due to immune complexes (e.g., splinter hemorrhages, conjunctival petechiae, Roth's spots, Osler's nodes, Janeway's lesions, microhematuria).
Note: Any patient enrolled in the study that is subsequently found to have LIE may be continued in the trial if determined to be clinically improving by the Investigator.
- Prosthetic heart valve;
- Baseline Creatinine clearance of <30 mL/min (as calculated by the Cockcroft-Gault equation using actual body weight);
- Baseline CPK value 5 X upper limit of normal (ULN) in conjunction with symptoms of myalgia or baseline CPK value 10 X ULN without symptoms;
- Alanine aminotransferase (ALT) >5 X ULN;
- Aspartate aminotransferase (AST) >5 X ULN;
- Moribund clinical condition (i.e. high likelihood of death within 3 days after randomization);
- Shock or hypotension (supine systolic blood pressure <80 mm Hg) or oliguria (urine output <20 mL/h) unresponsive to fluids or pressors within 4 hours;
- Known pneumonia or osteomyelitis;
- Polymicrobial infection or bacteremia due to a pathogen other than S. aureus;
- Neutropenia (absolute neutrophil count < 0.5 X 103/μL) and/or lymphopenia (CD4 lymphocytes <0.2X 103/μL);
- Anticipated to require non-study antibiotics that may be potentially effective against S. aureus;
- Prior gentamicin therapy > 1 day;
- Documented history of significant allergy or intolerance to any of the study medications;
- Unlikely to comply with study procedures;
- Pregnant or nursing. All females with childbearing potential will have a pregnancy test performed at the local laboratory.
- Female of childbearing potential and not willing to practice barrier methods of birth control (e.g., condoms or diaphragms together with spermicidal foam or gel) during treatment and for at least 28 days after treatment with study medication
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Daptomycin Alone
daptomycin 6 mg/kg q24h for treatment of right-sided infective endocarditis
|
Intravenous (i.v.) 6 mg/kg q24h
Other Names:
|
Experimental: Daptomycin plus gentamicin
daptomycin 6 mg/kg q24h with concomitant initial gentamicin dosed for the first 2 days of therapy for the treatment of right-sided infective endocarditis
|
i.v.
daptomycin 6 mg/kg q24h plus initial i.v.
gentamicin
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Summary of Clinically Significant Increases in Serum Creatinine by Visit
Time Frame: Baseline, EOT Visit, TOC
|
The End of Treatment (EOT)/Early Termination (ET) visit occurred on the day that therapy was stopped or up to 2 days after the last dose of daptomycin.
The Test of Cure (TOC)/Safety visit occurred 21 to 28 days after the last dose of daptomycin therapy.
The overall median duration of treatment was 13.0 days in both the daptomycin group and the combination therapy group.
The definition of elevated serum creatinine at baseline is >3.0 mg/dL, and not elevated is ≤3.0 mg/dL.
Clinically significant increases in serum creatinine is defined as an increase ≥0.5 mg/dL for patients with a baseline value ≤3.0 mg/dL or ≥1.0 mg/dL for patients with a baseline value >3.0 mg/dL.
|
Baseline, EOT Visit, TOC
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Summary of the Investigator's Assessment of Clinical Response at the TOC Visit
Time Frame: TOC Visit
|
TOC/Safety visit occurred 21 to 28 days after the last dose of daptomycin therapy.
Clinical response was assessed by the investigator as cure, improvement, failure, and unable to evaluate.
Microbiological response, which was determined by the sponsor based on review of baseline and post-baseline culture results, included success, failure, and nonevaluable.
TC=Treatment Cure; TF=Treatment Failure; TI=Treatment Improved.
|
TOC Visit
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Paula Bokesch, M.D., Cubist Pharmaceuticals LLC
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Heart Diseases
- Cardiovascular Diseases
- Infections
- Bacterial Infections
- Bacterial Infections and Mycoses
- Cardiovascular Infections
- Endocarditis, Bacterial
- Endocarditis
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Enzyme Inhibitors
- Anti-Bacterial Agents
- Protein Synthesis Inhibitors
- Gentamicins
- Daptomycin
Other Study ID Numbers
- 3009-010
- DAP-4IE-06-03 (Other Identifier: Cubist Study Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Infective Endocarditis
-
Emil Loldrup FosbolHvidovre University Hospital; Bispebjerg Hospital; Amager Hospital; Herlev and... and other collaboratorsRecruitingEndocarditis InfectiveDenmark, Netherlands, Sweden
-
LysovantWithdrawnEndocarditis Infective | Bacteremia Due to Staphylococcus Aureus | Left Sided Infective Endocarditis (Disorder) | Right Sided Infective Endocarditis (Disorder)United States
-
Fundacion Clinic per a la Recerca BiomédicaNot yet recruitingEndocarditis InfectiveSpain
-
Fondazione Policlinico Universitario Agostino Gemelli...RecruitingEndocarditis InfectiveItaly
-
Assistance Publique Hopitaux De MarseilleCompleted
-
Assistance Publique Hopitaux De MarseilleUnknownInfective Endocarditis (IE)France
-
Region SkaneCompleted
-
Assistance Publique - Hôpitaux de ParisNot yet recruitingProsthetic Valve EndocarditisFrance
-
Assiut UniversityRecruitingProsthetic Valve EndocarditisEgypt
-
Montreal Heart InstituteRecruitingInfective Endocarditis | Native Valve EndocarditisCanada
Clinical Trials on daptomycin
-
Cubist Pharmaceuticals LLCTerminatedWound Infections
-
Cubist Pharmaceuticals LLCCompletedGram Positive Infection | Concurrent Antibiotic TreatmentUnited States
-
Cubist Pharmaceuticals LLCCompletedBacteremia | Bacterial Endocarditis
-
University Hospital, CaenCompletedPeritoneal InfectionFrance
-
Merck Sharp & Dohme LLCCompleted
-
Cubist Pharmaceuticals LLCTerminatedGram-Positive Bacterial Infections
-
University of Maryland, BaltimoreCubist Pharmaceuticals LLCCompletedFasciitis, Necrotizing | Fournier's Gangrene | Severe Necrotizing Skin and Soft Tissue InfectionsUnited States
-
Cubist Pharmaceuticals LLCCompletedGram-positive Bacterial InfectionsUnited States
-
Cubist Pharmaceuticals LLCCompleted
-
Cubist Pharmaceuticals LLCCompleted